RxDoctor Payments Data

Urooj Fatima, MD

Interventional Cardiology · Washington, DCNPI 1750638045

Payments from drug & device makers

What this record shows

14 manufacturers reported payments, led by Abbott at 48.7% of the total. Reporting peaked in 2019 at $4,769 and has fallen 99.7% since, to $16 in 2025.

$7,381in general payments, 2019–2025

Across 79 payments — averaging $93.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Medtronic$2K
  • Boston Scientific$1K
  • Abiomed$183
  • Cardiovascular Systems Inc.$106
  • Getinge USA Sales, LLC$80
  • plus $258 from 8 others
$34in research payments, 2019–2025

Across 1 payment — averaging $33.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$34

What the payments were for

  • Travel & lodging$3,96954%
  • Food & beverage$3,41246%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few interventional cardiology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$46,357
Medicare patients
123
Services billed
372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban17$10,493
Labetalol Hcl11$339
Atorvastatin Calcium26$219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$10,49317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional cardiology providers in District of Columbiaon file to place this against a meaningful peer group, so we don't.

Other interventional cardiology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →